United States

TG Therapeutics announces successful outcome from first pre-planned interim analysis

Thursday, 10 Aug 2017 07:30am EDT 

Aug 10 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces successful outcome from the first pre-planned interim analysis by independent DSMB of the DLBCL cohort in the unity-NHL PHASE 2B trial.TG Therapeutics Inc - ‍DSMB recommends continued enrollment in TGR-1202 + TG-1101 arm and no further enrollment into single agent TGR-1202 arm​.TG Therapeutics Inc - ‍single agent TGR-1202 arm will be replaced with triple combination of TG-1101, TGR-1202 and bendamustine​.